Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Marcel van Den Brink
Sloan Kettering Inst Can Research, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Seres Therapeutics
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Under this grant there will be further study of how microbial community structure, associated metabolites, and nutritional and antibiotic manipulations thereof affect GVHD, with the goal of developing therapies that prolong survival and improve quality of life for bone-marrow transplant patients. Seres Therapeutics is a clinical biopharmaceutical company with a focus on microbiome-based therapeutics for the treatment of diseases that possess a microbiome signature characterized by dysbiosis. Dr. van den Brink is a co-inventor of the intellectual property that MSK licensed to Seres Therapeutics. Dr. van den Brink serves on the Seres SAB. The business interests of this company overlap with the focus of this research.
The role of intestinal microbiota in graft-versus-host disease
Allogeneic hematopoietic cell transplantation (allo-HCT) ?also called bone marrow transplantation?is a precision-medicine cancer therapy that can cure blood cancers, but is also accompanied by sometimes-lethal toxicities such as graft-vs-host disease (GVHD). Reinforcing the influence of gut microbiota communities on health and disease, we have previously identified features of the intestinal microbiota that predict important outcomes after transplantation in allo-HCT patients and animal models of GVHD. Here, we propose further study of how microbial community structure, associated metabolites, and nutritional and antibiotic manipulations thereof affect GVHD, with the goal of developing therapies that prolong survival and improve quality of life for bone-marrow transplant patients.
Filed on November 28, 2018.
Tell us what you know about Marcel van Den Brink's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Marcel van Den Brink filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Marcel van Den Brink | Sloan Kettering Inst Can Research | Conflict of Interest | Seres Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.